Merck Seeks Speedy Court Ruling on Medicare Price Negotiations

Merck & Co. is doubling down on its mission to block Medicare from negotiating the prices of drugs it spends the most on, requesting a ruling from a federal judge before the case can head to trial.

The pharmaceutical company, whose diabetes medication Januvia is likely to be selected for the first round of government price negotiations, filed a motion for summary judgment in the US District Court for the District of Columbia Tuesday. Merck will “imminently be subject to the program” under the Inflation Reduction Act when the Centers for Medicare & Medicaid Services in September announces the first ...